FDA Recalls Wells Pharmacy Testosterone and Anastrozole Pellets
Wells Pharmacy Network is recalling compounded Testosterone 200 mg/Anastrozole 9 mg Pellets because they are superpotent or subpotent.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class II, which corresponds to a 'Severe' rating (score 4) under the rubric, as it involves a potential health risk that may require medical treatment.
Plain-English summary
The U.S. Food and Drug Administration (FDA) is recalling Testosterone 200 mg/Anastrozole 9 mg Pellets compounded by Wells Pharmacy Network, LLC. The recall involves 690 pellets distributed in the U.S. The specific lots affected are identified by the following lot numbers and beyond-use dates: Lot 04072016@4 (BUD 10/04/2016), Lot 06162016@2 (BUD 12/03/2016), and Lot CA07112016@4 (BUD 01/07/2017).
The reason for the recall is that the products are classified as superpotent and subpotent drugs. This means the medication may contain more or less of the active ingredient than intended, which can affect its safety and effectiveness.
Consumers who have these specific pellets should stop using them and contact their healthcare provider or pharmacist for instructions on how to dispose of the product or obtain a replacement.
The recalled product
- Product
- Testosterone 200 mg/Anastrozole 9 mg Pellet, Compounded by: Wells Pharmacy Network
- Manufacturer
- Wells Pharmacy Network, LLC
- Category
- Drug — Compounded Medication
- Affected units
- 690
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- BUD: 10/04/2016
- Lot number 04072016@40 BUD: 12/03/2016
- Lot number 06162016@2 BUD: 01/07/2017
- Lot number CA07112016@4
Distribution
Distribution scope not specified by the agency.
Part of a larger recall action
This product is one of 7 recalled by Wells Pharmacy Network, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 7 products in this recall →Related recalls
Same manufacturer · Wells Pharmacy Network, LLC
See all →- SevereWells Pharmacy Recalls Injectable Compounds Due to Sterility Concerns
FDA (Drugs) · 2017-01-11
- SevereWells Pharmacy Recalls Compounded Chorionic Gonadotropin Injectable Kits
FDA (Drugs) · 2017-01-11
- SevereWells Pharmacy Recalls Compounded Injectable Due to Sterility Concerns
FDA (Drugs) · 2017-01-11
- SevereWells Pharmacy Recalls Trimix with Atropine Injectable Due to Sterility Concerns
FDA (Drugs) · 2017-01-11
- SevereWells Pharmacy Recalls Testosterone Cypionate Injectable Due to Sterility Concerns
FDA (Drugs) · 2017-01-11
Same hazard · superpotent drug
See all →- HighLevothyroxine Sodium Tablets Recalled Due to Potency Failures
FDA (Drugs) · 2024-12-18
- SevereLupin Recalls Cefprozil Oral Suspension Due to Superpotent Drug Concerns
FDA (Drugs) · 2021-04-21
- ModerateRocky Mountain Sunscreen Lip Balm Recalled for Excess Octisalate
FDA (Drugs) · 2020-09-02
- CriticalFerring Recalls STIMATE Nasal Spray Due to Superpotent Drug Risk
FDA (Drugs) · 2020-08-26
- CriticalFerring Recalls DDAVP Nasal Spray Due to Superpotent Drug Risk
FDA (Drugs) · 2020-08-26